Extracellular matrix regulation of drug resistance in small-cell lung cancer

References

• Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001; 20: 4995–5004
   PubMed Web of Science ®Google Scholar
• Bepler G, Jaques G, Neumann K, Aumuller G, Gropp C, Havemann K. Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines. Journal of Cancer Research and Clinical Oncology 1987; 113: 31–40
   PubMed Web of Science ®Google Scholar
• Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Seminars in Oncology 2002; 29: 78–86
   PubMed Web of Science ®Google Scholar
• Boonstra J. Progression through the G1-phase of the on-going cell cycle. Journal of Cellular Biochemistry 2003; 90: 244–252
   PubMed Web of Science ®Google Scholar
• Boudreau N, Sympson C j, Werb Z, Bissell M J. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995; 267: 891–893
   PubMed Web of Science ®Google Scholar
• Brakebusch C, Fassler R. Beta 1 integrin function in vivo: Adhesion, migration and more. Cancer Metastasis Reviews 2005; 24: 403–411
   PubMed Web of Science ®Google Scholar
• Bramhall S R, Hallissey M T, Whiting J, Scholefield J, Tierney G, Stuart R C, Hawkins R E, Mcculloch P, Maughan T, Brown P D, Baillet M, Fielding J W. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. British Journal of Cancer 2002; 86: 1864–1870
   PubMed Web of Science ®Google Scholar
• Brognard J, Clark A S, Ni Y, Dennis P A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Research 2001; 61: 3986–3997
   PubMed Web of Science ®Google Scholar
• Cappellini A, Tabellini G, Zweyer M, Bortul R, Tazzari P L, Billi A M, Fala F, Cocco L, Martelli A M. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukaemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia 2003; 17: 2157–2167
   PubMed Web of Science ®Google Scholar
• Diehl J A, Cheng M, Roussel M F, Sherr C J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes and Development 1998; 12: 3499–3511
   PubMed Web of Science ®Google Scholar
• Dou Q P, Lui V W. Failure to dephosphorylate retinoblastoma protein in drug resistant cells. Cancer Research 1995; 55: 5222–5225
   PubMed Web of Science ®Google Scholar
• Falcioni R, Cimino L, Gentileschi M P, D'Agnano I, Zupi G, Kennel S J, Sacchi A. Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes. Experimental Cell Research 1994; 210: 113–122
   PubMed Web of Science ®Google Scholar
• Fridman R, Giaccone G, Kanemoto T, Martin G R, Gazdar A F, Mulshine J L. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proceedings of the National Acadamy of Science USA 1990; 87: 6698–6702
   PubMed Web of Science ®Google Scholar
• Gregorc V, Ludovini V, Pistola L, Darwish S, Floriani I, Bellezza G, Sidoni A, Cavaliere A, Scheibel M, De Angelis V, Bucciarelli E, Tonato M. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced nonsmall cell lung cancer. Lung Cancer 2003; 39: 41–48
   PubMed Web of Science ®Google Scholar
• Hannun Y A. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845–1853
   PubMed Web of Science ®Google Scholar
• Hannun Y A, Obeid L M. Mechanisms of ceramide-mediated apoptosis. Advances in Medical and Experimental Biology 1997; 407: 145–149
   PubMed Web of Science ®Google Scholar
• Hazlehurst L A, Damiano J S, Buyuksal I, Pledger W J, Dalton W S. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19: 4319–4327
   PubMed Web of Science ®Google Scholar
• Hazlehurst L A, Valkov N, Wisner L, Storey J A, Boulware D, Sullivan D M, Dalton W S. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001; 98: 1897–1903
   PubMed Web of Science ®Google Scholar
• Hirasawa M, Shijubo N, Uede T, Abe S. Integrin expression and ability to adhere to extracellular matrix proteins and endothelial cells in human lung cancer lines. British Journal of Cancer 1994; 70: 466–473
   PubMed Web of Science ®Google Scholar
• Hodkinson P S, Elliott T, Wong W S, Rintoul R C, Mackinnon A C, Haslett C, Sethi T. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death and Differentiation 2006; 13: 1776–1788
   PubMed Web of Science ®Google Scholar
• Hovelmann S, Beckers T L, Schmidt M. Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. British Journal of Cancer 2004; 90: 2370–2377
   PubMed Web of Science ®Google Scholar
• Hoyt D G, Rusnak J M, Mannix R J, Modzelewski R A, Johnson C S, Lazo J S. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Research 1996; 56: 4146–4149
   PubMed Web of Science ®Google Scholar
• Hui R, Finney G L, Carroll J S, Lee C S, Musgrove E A, Sutherland R L. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Research 2002; 62: 6916–6923
   PubMed Web of Science ®Google Scholar
• Hynes R O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11–25
   PubMed Web of Science ®Google Scholar
• Katori H, Baba Y, Imagawa Y, Nishimura G, Kagesato Y, Takagi E, Ishii A, Yanoma S, Maekawa R, Yoshioka T, Nagashima Y, Kato Y, Tsukuda M. Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Letters 2002; 178: 151–159
   PubMed Web of Science ®Google Scholar
• Kouniavsky G, Khaikin M, Zvibel I, Zippel D, Brill S, Halpern Z, Papa M. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clinical Experimental Metastasis 2002; 19: 55–60
   PubMed Web of Science ®Google Scholar
• Lauffenburger D A. Cell motility. Making connections count. Nature 1996; 383: 390–391
   PubMed Web of Science ®Google Scholar
• Lauffenburger D A, Horwitz A F. Cell migration: a physically integrated molecular process. Cell 1996; 84: 359–369
   PubMed Web of Science ®Google Scholar
• Lein M, Jung K, Ortel B, Stephan C, Rothaug W, Juchem R, Johannsen M, Deger S, Schnorr D, Loening S, Krell H W. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 2002; 21: 2089–2096
   PubMed Web of Science ®Google Scholar
• Liu B Q, Peto R, Chen Z M, Boreham J, Wu Y P, Li J Y, Campbell T C, Chen J S. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. British Medical Journal 1998; 317: 1411–1422
   PubMed Web of Science ®Google Scholar
• Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Research 1999; 59: 1252–1258
   PubMed Web of Science ®Google Scholar
• Luscinskas F W, Lawler J. Integrins as dynamic regulators of vascular function. FASEB Journal 1994; 8: 929–938
   PubMed Web of Science ®Google Scholar
• Macaulay V M, O'Byrne K J, Saunders M P, Braybrooke J P, Long L, Gleeson F, Mason C S, Harris A L, Brown P, Talbot D C. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clinical Cancer Research 1999; 5: 513–520
   PubMed Web of Science ®Google Scholar
• Massague J. G1 cell-cycle control and cancer. Nature 2004; 432: 298–306
   PubMed Web of Science ®Google Scholar
• Mazumder S, Dupree E L, Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Current Cancer Drug Targets 2004; 4: 65–75
   PubMed Web of Science ®Google Scholar
• Mettouchi A, Meneguzzi G. Distinct roles of beta 1 integrins during angiogenesis. European Journal of Cell Biology 2006; 85: 243–247
   PubMed Web of Science ®Google Scholar
• Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd F A. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. Journal of Clinical Oncology 1999; 17: 1802–1808
   PubMed Web of Science ®Google Scholar
• Mitsiades C S, Mitsiades N, Koutsilieris M. The Akt pathway: Molecular targets for anti-cancer drug development. Current Cancer Drug Targets 2004; 4: 235–256
   PubMed Web of Science ®Google Scholar
• Naglich J G, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson A J, Lewin A C, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer R A, Trail P A. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Research 2001; 61: 8480–8485
   PubMed Web of Science ®Google Scholar
• Osterlind K, Hansen H H, Hansen M, Dombernowsky P, Andersen P K. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants. Journal of Clinical Oncology 1986; 4: 1307–1313
   PubMed Web of Science ®Google Scholar
• Page K, Li J, Wang Y, Kartha S, Pestell R G, Hershenson M B. Regulation of cyclin D(1) expression and DNA synthesis by phosphatidylinositol 3-kinase in airway smooth muscle cells. American Journal of Respiratory Cell and Molecular Biology 2000; 23: 436–443
   PubMed Web of Science ®Google Scholar
• Phillips-Mason P J, Raben D M, Baldassare J J. Phosphatidylinositol 3-kinase activity regulates alpha -thrombin-stimulated G1 progression by its effect on cyclin D1 expression and cyclin-dependent kinase 4 activity. Journal of Biological Chemistry 2000; 275: 18046–18053
   PubMed Web of Science ®Google Scholar
• Resnitzky D. Ectopic expression of cyclin D1 but not cyclin E induces anchorage-independent cell cycle progression. Molecular Cell Biology 1997; 17: 5640–5647
   PubMed Web of Science ®Google Scholar
• Rintoul R C, Buttery R C, Mackinnon A C, Wong W S, Mosher D, Haslett C, Sethi T. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Molecular Biology of the Cell 2002; 13: 2841–2852
   PubMed Web of Science ®Google Scholar
• Rintoul R C, Sethi T. The role of extracellular matrix in small-cell lung cancer. Lancet Oncology 2001; 2: 437–442
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hovelmann S, Beckers T L. A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. British Journal of Cancer 2002; 87: 924–932
   PubMed Web of Science ®Google Scholar
• Sethi T, Rintoul R C, Moore S M, Mackinnon A C, Salter D, Choo C, Chilvers E R, Dransfield I, Donnelly S C, Strieter R, Haslett C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Medicine 1999; 5: 662–668
   PubMed Web of Science ®Google Scholar
• Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: Effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Research 1991; 51: 3621–3623
   PubMed Web of Science ®Google Scholar
• Shepherd F A, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. Journal of Clinical Oncology 2002; 20: 4434–4439
   PubMed Web of Science ®Google Scholar
• Sherr C J, Roberts J M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development 1999; 13: 1501–1512
   PubMed Web of Science ®Google Scholar
• Sixt M, Bauer M, Lammermann T, Fassler R. Beta1 integrins: Zip codes and signaling relay for blood cells. Current Opinions in Cell Biology 2006; 18: 482–490
   PubMed Web of Science ®Google Scholar
• Smith P J, Soues S, Gottlieb T, Falk S J, Watson J V, Osborne R J, Bleehen N M. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. British Journal of Cancer 1994; 70: 914–921
   PubMed Web of Science ®Google Scholar
• Smith P J, Wiltshire M, Chin S F, Rabbitts P, Soues S. Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells. International Journal of Radiation Biology 1999; 75: 1137–1147
   PubMed Web of Science ®Google Scholar
• Su J M, Gui L, Zhou Y P, Zha X L. Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance. World Journal of Gastroenterology 2002; 8: 613–618
   PubMed Web of Science ®Google Scholar
• Tian B, Lessan K, Kahm J, Kleidon J, Henke C. Beta 1 integrin regulates fibroblast viability during collagen matrix contraction through a phosphatidylinositol 3-kinase/Akt/protein kinase B signaling pathway. Journal of Biological Chemistry 2002; 277: 24667–24675
   PubMed Web of Science ®Google Scholar
• Tong W, Pollard J W. Genetic evidence for the interactions of cyclin D1 and p27(Kip1) in mice. Molecular and Cellular Biology 2001; 21: 1319–1328
   PubMed Web of Science ®Google Scholar
• Uhm J H, Dooley N P, Kyritsis A P, Rao J S, Gladson C L. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clinical Cancer Research 1999; 5: 1587–1594
   PubMed Web of Science ®Google Scholar
• Vidal A, Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene 2000; 247: 1–15
   PubMed Web of Science ®Google Scholar
• Woo R A, Poon R Y. Cyclin-dependent kinases and S phase control in mammalian cells. Cell Cycle 2003; 2: 316–324
   PubMed Web of Science ®Google Scholar
• Wu A H, Henderson B E, Thomas D C, Mack T M. Secular trends in histologic types of lung cancer. Journal of the National Cancer Institute 1986; 77: 53–56
   PubMedGoogle Scholar
• Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases −2, −9 and tissue inhibitors of metalloproteinases −1, −2 in lung cancer – TIMP-1 as a prognostic marker. Anticancer Research 2000; 20: 1311–1316
   PubMed Web of Science ®Google Scholar